Acute myelocytic leukemia (AML)
Conditions
Interventions
Group A:HAA regimen: Hom 2mg/m2 im or ivgtt qd day 1-7, Acla 20mg ivgtt qd day 1-7, Ara-C 100 mg/ m2 ivgtt, day 1-7
Group B:HAD regimen: Hom 2mg/m2 im or ivgtt qd day 1-7 DNR 40mg/m2 iv qd day 1-3 Ara-C 100mg/m2 ivgtt, day 1-7
Group C:DA regimen: DNR 40 mg/ m2 iv qd day1-3
Ara-C 100 mg/ m2 ivgtt, day 1-7
Sponsors
Ruijin Hospital affiliated to Shanghai Jiaotong University Medical College
Eligibility
Sex/Gender
All
Age
14 Years to 59 Years
Inclusion criteria
Inclusion criteria: 1. Patients with initial treatment of AML; 2. Age: 14-59 years; 3. Normal Liver and kidney functions (Serum hemobilirubin <=35umol/L. AST/ALT is lower than twice normal maximum level. Serum creatinine <=150umol/L); 4. Normal heart functions; 5. Physical score 0-2 grade (WHO standard).
Exclusion criteria
Exclusion criteria: 1. Patients with retreatment of AML; 2. Patients used other antitumor drug in the chemotherapy besides HAA, HAD or DA; 3. Patients with other types of carcinoma; 4. Patients with Tuberculosis; 5. patients with secondary leukemia; 6. Patients with other hematopathy; 7. Women who are pregnant or lactated; 8. Patients who can not understand or comply the research protocol; 9. Patients who are intolerated or allergy to the drug used in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-year disease free survival;relapse-free survival;5-year overall survival; | — |
Countries
China
Contacts
Public ContactJie Jin
Outcome results
None listed